Document Detail

Bronchodilator action of the anticholinergic drug, ipratropium bromide (Sch 1000), as an aerosol in chronic bronchitis and asthma.
MedLine Citation:
PMID:  138578     Owner:  NLM     Status:  MEDLINE    
Ipratropium bromide (also known as Sch 1000) is a new atropine-like bronchodilator drug whose mechanism of action is via an anticholinergic pathway and may decrease cyclic guanosine monophosphate. Although of established efficacy in asthma, there are no studies of the use of ipratropium in patients with chronic bronchitis. The single metered aerosol doses of 10 mug, 20 mug, 40 mug and 80 mug of ipratropium bromide, 75 mug and 150 mug of isoproterenol, and placebo were studied in 20 adult patients, half with asthma and half with chronic bronchitis. To qualify, all patients demonstrated at least 20% improvement in the forced expiratory volume in one second while in the drug-free state when tested with isoproterenol. All subjects were tested for six hours with each agent in a double-blind crossover design. The dose-response aspects of the study indicate that in bronchial asthma the optimal range of dosage is 40 mug to 80 mug of ipratropium bromide. These doses are superior to isoproterenol in duration of action. In chronic bronchitis, all doses of ipratropium showed prolonged efficacy, but 80 mug was superior. Isoproterenol lacked this sustained efficacy. No significant alteration in pulse or blood pressure was observed. Ipratropium appears to be an important addition to the bronchodilator agents used in isoproterenol-responsive obstructive pulmonary disease.
W Baigelman; S Chodosh
Related Documents :
8882478 - Increased neutrophil chemotactic activity is noted in alminum-induced occupational asthma.
9032178 - Observations on the effects of aerosolized albuterol in acute asthma.
3134808 - Prevention of non-specific bronchial hyperreactivity. dose-dependent effect of sodium c...
8720308 - Antipyretic effect of lumbricus spencer in acetylsalicylic acid-induced asthma.
20963598 - Adherence of hospital-based cardiologists to lipid guidelines in patients at high risk ...
17389558 - Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hyp...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Chest     Volume:  71     ISSN:  0012-3692     ISO Abbreviation:  Chest     Publication Date:  1977 Mar 
Date Detail:
Created Date:  1977-04-28     Completed Date:  1977-04-28     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0231335     Medline TA:  Chest     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  324-8     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Asthma / drug therapy*
Atropine Derivatives*
Bronchitis / drug therapy*
Bronchodilator Agents / administration & dosage*,  therapeutic use
Chronic Disease
Clinical Trials as Topic
Drug Evaluation
Forced Expiratory Volume
Ipratropium / administration & dosage*,  therapeutic use
Isoproterenol / administration & dosage,  therapeutic use
Parasympatholytics / administration & dosage,  therapeutic use
Time Factors
Reg. No./Substance:
0/Aerosols; 0/Atropine Derivatives; 0/Bronchodilator Agents; 0/Parasympatholytics; 0/Placebos; 60205-81-4/Ipratropium; 7683-59-2/Isoproterenol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The effect of Sch 1000 and disodium cromoglycate on exercise-induced asthma.
Next Document:  Exercising pulmonary blood flow in mitral stenosis with anomalous pulmonary venous connection.